This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1.
Non Hodgkin Lymphoma
This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1.
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
-
Stanford University, Stanford, California, United States, 94305
Yale University, New Haven, Connecticut, United States, 06520
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States, 21201
Dana Farber Cancer Institute, Boston, Massachusetts, United States, 02215
Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States, 53226
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Miltenyi Biomedicine GmbH,
Remi Kaleta, MD, STUDY_DIRECTOR, Miltenyi Biomedicine GmbH
2039-12-01